MedTrace Logo

Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II

NCT02743416 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 6868

Last updated 2020-11-25

No results posted yet for this study

Summary

STROKESTOP II will study if the biomarker NT-proBNP together with single-lead ECG can be used as a primary population screening tool for silent atrial fibrillation, and builds on previous results from the STROKESTOP study.

Conditions

Interventions

OTHER

ECG screening (Zenicor-ECG) for atrial fibrillation

Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.

Sponsors & Collaborators

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Mårten Rosenqvist, MD · Karolinska Institutet

Eligibility

Min Age
75 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743416 on ClinicalTrials.gov